Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2017 05/18/2017 05/19/2017 05/22/2017 05/23/2017 Date
446.72(c) 457.33(c) 450.01(c) 460.99(c) 461.37(c) Last
750 078 1 107 622 996 846 782 901 573 858 Volume
-1.77% +2.38% -1.60% +2.44% +0.08% Change
More quotes
Financials ($)
Sales 2017 5 481 M
EBIT 2017 2 210 M
Net income 2017 1 019 M
Finance 2017 2 119 M
Yield 2017 -
Sales 2018 6 157 M
EBIT 2018 2 613 M
Net income 2018 1 296 M
Finance 2018 2 844 M
Yield 2018 -
P/E ratio 2017 52,46
P/E ratio 2018 40,87
EV / Sales2017 8,56x
EV / Sales2018 7,50x
Capitalization 49 039 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
Sector
Biotechnology & Medical Research
Calendar
06/09 | 04:30pmShareholder meeting
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
10:39a SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 BIOTECH MOVERS : Puma Biotechnology Inc (NASDAQ:PBYI) and Regeneron Pharmaceutic..
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/22 REGENERON PHARMACEUTICALS : and Sanofi Announce FDA Approval of Kevzara® (sarilu..
05/19 REGENERON PHARMACEUTICALS : Pharma exec says industry must get fair about pricin..
05/18 REGENERON PHARMACEUTICALS : and Inovio Enter Immuno-Oncology Clinical Study Agre..
05/18 REGENERON PHARMACEUTICALS : and SillaJen Announce Immuno-Oncology Clinical Study..
05/18 REGENERON PHARMACEUTICALS : New Science Findings from Regeneron Pharmaceuticals ..
05/18 REPORTS OUTLINE THERAPEUTICS STUDY R : mitigating...
05/18 REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
09:50aSanofi, Regeneron set Kevzara up for tough RA turf battle with $39K list pric..
2
12:30aSanofi, Regeneron set Kevzara up for tough RA turf battle with $39K list pric.. 
05/23Regeneron Pharmaceuticals Inc $REGN Shares Bought by Mitsubishi UFJ Trust &am.. 
05/23Regeneron Pharmaceuticals Inc $REGN Position Raised by Mutual of America Capi.. 
05/23ICYMI: After Monday's market close, $SNY, $REGN won approval for RA therapy, .. 
More tweets
Qtime:91
News from SeekingAlpha
05/23 Sanofi and Regeneron's RA med Kevzara faces crowded market
05/22 Regeneron, Sanofi rheumatoid arthritis drug wins FDA approval
05/19 Congo reports rise in Ebola cases, now 29
05/19 REGENERON PHARMACEUTICALS : Post-Earnings Analysis
05/18 ESPERION THERAPEUTICS : Up, Up, And Away?
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 446 $
Spread / Average Target -3,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..25.58%48 999
AMGEN, INC.5.38%112 531
CELGENE CORPORATION1.35%90 349
GILEAD SCIENCES, INC.-9.66%84 101
ACTELION LTD25.17%30 824
VERTEX PHARMACEUTICALS..58.26%29 624
More Results